TriSalus Life Sciences (TLSI) Accumulated Expenses (2020 - 2026)

TriSalus Life Sciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 15.9% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 15.9% decrease from a year earlier, with the FY2025 full-year figure at $8.1 million, up 10.07% from the prior year.
• Accumulated Expenses slipped to $7.1 million in Q1 2026 per TLSI's latest filing, from $8.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.4 million in Q1 2024 and bottomed at $6.4 million in Q4 2022.
• The 5-year median for Accumulated Expenses is $7.6 million (2024), against an average of $8.1 million.
• Across the five-year window, Accumulated Expenses surged 65.53% in 2023 and plunged 30.32% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $6.4 million in 2022, then jumped by 65.53% to $10.6 million in 2023, then slumped by 30.32% to $7.4 million in 2024, then grew by 10.07% to $8.1 million in 2025, then retreated by 12.71% to $7.1 million in 2026.
• Per Business Quant, the three latest TLSI Accumulated Expenses figures stand at $7.1 million (Q1 2026), $8.1 million (Q4 2025), and $6.8 million (Q3 2025).